Tag: Chugai

October 30, 2019 Off

EMA and FDA Accept Marketing Applications for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

By BusinessWire

NMOSD is a rare disease where repeated relapses may result in visual impairment and motor disability in the course of…

October 30, 2019 Off

Chugai’s Hemlibra Approved for Hemophilia A Without Inhibitors in Taiwan

By BusinessWire

Hemlibra was approved for hemophilia A without inhibitors in Taiwan on 22 October 2019.

Chugai Presents Results from Second Positive Global Phase III Clinical Study of Satralizumab in NMOSD at ECTRIMS 2019

September 12, 2019 Off

Chugai Presents Results from Second Positive Global Phase III Clinical Study of Satralizumab in NMOSD at ECTRIMS 2019

By BusinessWire

Following a positive study where satralizumab was added to baseline therapy, satralizumab monotherapy significantly reduced risk of relapse by 55%…